Greywolfe CEO Ron Earley to Headline Oxford Keynote on the Future of AI and E-Commerce
How Machine Learning Is Reshaping Operational Strategy and Financial Freedom for the Next Generation of Entrepreneurs
OXFORD, United Kingdom, May 17, 2025 (GLOBE NEWSWIRE) -- Ron Earley, Founder and CEO of Greywolfe Investing, will deliver a featured keynote at the EMBA Inspires event hosted by Saïd Business School at the University of Oxford on May 19, 2025. This year's program focuses on Machine Learning Fundamentals, uniting global executives and Oxford's Executive MBA alumni to explore how artificial intelligence is transforming modern leadership and business strategy.
Earley's keynote, titled 'Scaling Smarter – AI, Strategy & the Amazon Wholesale Ecosystem,' will explore how artificial intelligence is transforming the Amazon FBA landscape. By drawing on real-world experience and case studies, he'll show how wholesale sellers are using machine learning tools to overcome operational blind spots, optimize performance, and scale more strategically. From predictive analytics to dynamic pricing, the session will highlight how business leaders can unlock efficiency and growth by integrating AI at key points across their organizations.
Earley will also challenge attendees to rethink how they structure teams, make decisions, and protect data as a strategic asset. His approach blends tactical insight with a long-term vision for responsible AI adoption, offering participants a rare look at how automation, culture, and clarity can combine to drive resilience in a volatile business environment.
'AI isn't just a tool, it's a multiplier of talent, speed, and insight,' said Earley. 'This keynote is about showing leaders how to move from reactive management to proactive strategy using real-world applications of machine learning.'
Ron Earley brings a unique entrepreneurial journey to Oxford's stage. From starting with just $36,000 in capital to building one of the fastest-growing Amazon FBA firms in the country, he has led Greywolfe Investing with a focus on transparency, automation, and operational excellence. His firm is headquartered next to Florida's largest Amazon facility, employs over 100 professionals, and is a member of Amazon's exclusive Service Provider Network.
Through the keynote, Earley will share insights on overcoming human limitations in managing complex e-commerce data, identifying and integrating automation opportunities, and transitioning organizations from instinct-driven cultures to AI-literate, structured environments. The session will also touch on emerging technologies shaping the future of commerce, including voice interfaces, generative content, and ethical AI systems.
Ron Earley's participation in EMBA Inspires reflects a growing recognition of the role entrepreneurs play in shaping how advanced technologies are applied in the real world. His keynote will not only highlight the technical possibilities of machine learning, but also ground them in the lived experience of building a business from the ground up. As leaders across industries look to integrate AI more thoughtfully, Earley's story offers a compelling reminder that innovation is most powerful when paired with clarity, strategy, and purpose.
About Greywolfe Investing:
Greywolfe Investing is a Sarasota-based e-commerce investment firm redefining how wholesale sellers succeed on Amazon. Specializing in Fulfilled by Amazon (FBA) operations, Greywolfe offers a fully integrated approach that combines proprietary AI tools, strategic warehousing near Amazon's largest Florida hub, and partnerships with some of the largest manufacturers in the world. As an official Amazon Service Provider Network (SPN) partner, the company is committed to building resilient, transparent, and scalable operations for investors and entrepreneurs alike. Greywolfe's mission is to create legitimate investment opportunities that prioritize both performance and long-term stability in the rapidly evolving e-commerce ecosystem.
Contact:
Ron Earley
[email protected]
Media contact:
Chloe Smart
[email protected]A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4d4d7e91-7583-4964-8a8e-72f35829dbb2
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
8 minutes ago
- Bloomberg
Nvidia, Samsung Plan Investments in Robotics Startup Skild AI
Samsung Electronics Co. and Nvidia Corp. will take minority stakes in Skild AI Inc. as they seek to bolster their work in the emerging consumer robotics industry. The South Korean tech leader is making a $10 million investment in Skild, which develops software for robots, according to people with knowledge of the matter. The Santa Clara, California chipmaker is putting in $25 million, said the people, who asked not to be identified discussing unannounced plans.
Fast Company
23 minutes ago
- Fast Company
Enough hype about AI in health—let's talk about results
There's no shortage of big promises about AI in healthcare. The U.S. government announced a $500 billion Stargate initiative to fund AI infrastructure, while the UK government announced £82.6 million in research funding for three projects, two of which are using AI to tackle cancer and Alzheimer's disease. But ask any patient waiting for a diagnosis, or a clinician searching for certainty, and the real question cuts through all the noise: When will all the innovation deliver real impact where it matters most? We've entered an era where healthcare data is measured in exabytes—genomes, images, clinical notes, labs, and signals from every continent. At SOPHiA GENETICS, we've just achieved the milestone of analyzing 2 million patient profiles. It's a number that was unimaginable a decade ago. Yet the value of data isn't in volume. It's what you do with it. Insight matters only if it changes an outcome, shortens a diagnostic odyssey, or opens up a new chance for a patient. It's time to move from conversation to action. Too often, insights get trapped in institutional silos or left in endless pilot projects, just out of reach of the people who need them. 3 ways AI is already transforming medicine Today, technology can connect, for example, a patient in São Paulo with expertise in Seoul, uncovering patterns invisible to the human eye. Here are several ways AI is helping now. 1. Improving diagnostic accuracy: AI algorithms, particularly those based on deep learning, have demonstrated remarkable accuracy in diagnosing diseases from medical images and test results. These systems are trained on vast datasets, allowing them to recognize patterns and anomalies that might be missed by the human eye. For example, in dermatology, AI systems trained on images of skin lesions have shown the ability to detect skin cancers, such as melanoma, with high levels of precision. 2. Enhancing cancer prevention: AI techniques can be used to screen individuals for genomic markers and develop personalized cancer risk prediction scores. This proactive approach can help screen younger patients for genomic predispositions, empowering them to make informed prevention decisions and proactively monitor their health. 3. Tailoring treatments to genomic profiles: One of the most significant applications of AI is in the field of genomics. AI can analyze vast genomic datasets to identify mutations and variations that might influence an individual's response to certain treatments. For example, our SOPHiA DDM product can identify specific genomic markers that are susceptible to targeted cancer therapies, increasing the efficacy of the treatment and minimizing the risk of adverse reactions, for a more effective and safer treatment plan for patients. To scale up these AI applications there are many regulatory and compliance barriers to overcome. This requires investment in data security, creating clear guidelines, data security measures, and ensuring clinicians are fully trained. Our goal should be to create a regulatory environment that fosters innovation while safeguarding patient data and promoting public trust. We must democratize this powerful data to enable more physicians, practices, and hospitals to incorporate AI into daily clinical use so that a greater number of patients can access data-driven medicine, not just a select few. My message for governments investing in AI is clear: Balance investing in future AI tools with validating existing solutions that have already been proven to improve patient outcomes. Build the bridges that turn breakthroughs into benefits, so that data-driven medicine becomes a reality for every patient.
Yahoo
25 minutes ago
- Yahoo
NewAmsterdam Pharma Company N.V. (NAMS) Initiated with a Buy at Stifel
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is one of the 13 Biotech Stocks with Huge Upside Potential. It is now under Stifel's coverage, with a buy rating and a $44 price target. A scientist in a lab coat standing in a research lab examining biopharmaceuticals. According to the firm, NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a distinct late-stage cardiovascular company with a short-term trajectory toward regulatory filings. Its core asset, obicetrapib, has the potential to differentiate itself in the growing lipid-lowering market, according to Stifel. The analyst points out that obicetrapib potentially differs from earlier attempts in the CETP inhibitor market due to the company's cardiovascular outcomes trial, PREVAIL. Stifel anticipates significant upside even under cautious commercial assumptions. The CETP inhibitor obicetrapib, which is being developed by NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), is intended to decrease cholesterol in the treatment of cardiovascular disease. Stifel cites the PREVAIL study and an extensive amount of supporting data to show that obicetrapib differs significantly from previous CETP failures. New Amsterdam has a legitimate route to market access due to this distinction and impending regulatory milestones. Stifel's $44 price estimate shows that they are confident in the drug's clinical uniqueness and market potential. While we acknowledge the potential of NAMS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
